Cherkez S, Herzig J, Yellin H
J Med Chem. 1986 Jun;29(6):947-59. doi: 10.1021/jm00156a011.
The synthesis of the isomeric series 6-chloro-7-sulfamoyl- and 7-chloro-6-sulfamoyl-1(2H)-phthalazinones (1 and 2) and 6-chloro-7-sulfamoyl- and 7-chloro-6-sulfamoyl-3,4-dihydo-1(2H)-phthalazinones (3 and 4), combining structural features characteristic to furosemide and hydralazine, is described, the mechanism of the formation of 1 and 2 is discussed, and their structure-activities relationships are studied. Preliminary screening in the rat shows that series 1 and 3 exhibit diuretic and saluretic activity similar to that of chlorothiazide with, however, Na+/K+ ratios more favorable than chlorothiazide and furosemide. The compounds of series 2 and 4 are practically inactive. All four series show initial antihypertensive activity lower than that of hydralazine. However, compounds 1a, 1c, and 4a show a higher activity at 8 and/or 24 h after administration and thus may offer a unique combination of a "loop" diuresis with direct long-acting peripheral vasodilating effects.
描述了6-氯-7-氨磺酰基-和7-氯-6-氨磺酰基-1(2H)-酞嗪酮(1和2)以及6-氯-7-氨磺酰基-和7-氯-6-氨磺酰基-3,4-二氢-1(2H)-酞嗪酮(3和4)的异构体系列的合成,该系列结合了速尿和肼屈嗪的特征结构特点,讨论了1和2的形成机制,并研究了它们的构效关系。在大鼠中的初步筛选表明,系列1和3表现出与氯噻嗪相似的利尿和促尿钠排泄活性,然而,其钠/钾比优于氯噻嗪和速尿。系列2和4的化合物实际上没有活性。所有四个系列的初始降压活性均低于肼屈嗪。然而,化合物1a、1c和4a在给药后8小时和/或24小时表现出更高的活性,因此可能提供“袢”利尿与直接长效外周血管舒张作用的独特组合。